Spend $99, get free U.S. shipping*
Tariff now required on U.S. shipments. Learn more »
Tel: 1-866-456-3768 Fax: 1-866-544-8993
For visual reference only; actual product may vary
For visual reference only; actual product may vary
NovoSeven RT is an injectable medication used to control bleeding episodes and prevent bleeding during surgeries and procedures in adults and children with specific bleeding disorders such as hemophilia.
| Novoseven RT Brand | 2mg/vial 1 Vial |
-
|
Our price: $1,460.00 |
|
| Novoseven RT Brand | 1mg/vial 1 Vial |
-
|
Our price: $730.00 |
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.Â
NovoSeven RT may cause serious blood clots that form in veins and arteries. Doctors should have discussed the risks and explained the signs and symptoms of blood clots. Some of these include pain, swelling, warmth, redness, or a lump in the legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function. Healthcare providers usually monitor patients for signs of blood clots during treatment.
Doctors prescribe this medication because they assess the benefits of such treatment outweigh any likely unwanted effects.
Some of the side effects that have been reported include fever, headache, dizziness, nausea, or vomiting may occur.Â
Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.
Patients who have blood-clotting disorders such as hemophilia types A and B may require special blood-clotting facilitation if they have uncontrolled bleeding episodes after injury or are having to underego surgical procedures. Factor VIIa is a man-made protein that mimics the naturally occurring clotting activator in the body. It is used to stop bleeding in patients by helping the blood to clot.
Factor VIIa is a synthetic protein produced to replicate the activated factor VII (factor VIIa) in the body that promoes clotting. It is used to stop bleeding from injuries or surgical procedures for patients with hemophilia by helping the blood to clot. Factor VIIa is to be given only by or under the direct supervision of a doctor.
Recombinanat factor VIIa activates factors IX and X, which in turn activates factor V, which converts prothrombin to thrombin. Thrombin creates a thrombin burst, which converts fibrinogen to fibrin for clot formation
Studies in adults showed that the circulating half-life of rfVIIa is between 2.60 to 2.84 hours, independent of dose.
Hemophilia A and B are both the results of a deficiency in blood clotting factors. Hemophilia A is caused by a deficiency of factor VIII, while Hemophilia B is caused by a deficiency of factor IX.
Both forms of hemophilia (A and B) are X-linked recessive disorders, which means they are more common in males and can only be inherited from maternal grandfathers who have the faulty gene. Mothers who inherit the gene from their fathers don't have any symptoms. Very rarely, a gene mutation can occur, which could start a new line of inheritance. This is believed to have happened in the case of Queen Victoria, who passed the gene on to many of the males in the royal families of Europe in the 19th century.
Send Your Prescription
No Hidden Fees
Generally 7-10 Business Days
IsraelPharm has been delivering lost cost prescriptions from Israel for over 15 years worldwide. Daily flights allow us to get your medications dispatched fast! Delivery to the USA is under 10 days and you can track and trace every order.
Infections can trigger more than short-term illness. Infections are often treated as temporary setbacks – unpleasant, sometimes serious, but ultimately self-limiting. Increasingly, that view is being challenged. A growing body of research shows that post-infection
The idea of AI therapy is no longer science fiction. It is already here, quietly shaping how people think about emotional support and mental health care. From late-night conversations with chatbots to structured therapy apps,
1st April marks the start of the annual Parkinson’s Awareness Month. This year, we will focus on some of the positive advances in the treatment of Parkinson’s disease (PD). This progressive neurological condition affects movement
